CAJ | 학술논문

目的评价贝伐单抗联合IFL方案(伊立替康、氟尿嘧啶、亚叶酸钙)治疗既往接受过以草酸铂为主的化疗方案的进展期转移性结直肠癌的疗效和安全性.方法回顾性总结2004年7月至2006年6月间分别予以贝伐单抗联合IFL方案(A组,30例)和单纯使用IFL方案(B组,32例)进行化疗患者的治疗后反应率、治疗中不良反应和治疗前后血清肿瘤标志物的动态变化及随访1年的生存率.结果 A组和B组的有效率分别为30.0%和21.8%:疾病控制率分别为80%和50%.所有患者治疗前后肿瘤标志物的浓度均有明显变化(P<0.05),A组与B组比较.差异有统计学意义(P<0.05).两组均未出现明显的Ⅲ、Ⅳ度不良反应,两组间不良反应的差异无统计学意义(P>0.05).A、B两组患者1年存活率分别为26.7%和18.8%.中位疾病进展时间分别为5.9个月和3.9个月,中位总生存期分别为10.9个月和8.9个月.差异均有统计学意义(P<0.05).结论与单纯使用IFL方案相比.贝伐单抗联合IFL方案能进一步延长既往接受过以草酸铂为主化疗方案的转移性结直肠癌患者的生存时间,治疗耐受性良好.
목적 평개패벌단항연합IFL방안(이립체강、불뇨밀정、아협산개)치료기왕접수과이초산박위주적화료방안적진전기전이성결직장암적료효화안전성.방법 회고성총결2004년7월지2006년6월간분별여이패벌단항연합IFL방안(A조,30례)화단순사용IFL방안(B조,32례)진행화료환자적치료후반응솔、치료중불량반응화치료전후혈청종류표지물적동태변화급수방1년적생존솔.결과 A조화B조적유효솔분별위30.0%화21.8%:질병공제솔분별위80%화50%.소유환자치료전후종류표지물적농도균유명현변화(P<0.05),A조여B조비교.차이유통계학의의(P<0.05).량조균미출현명현적Ⅲ、Ⅳ도불량반응,량조간불량반응적차이무통계학의의(P>0.05).A、B량조환자1년존활솔분별위26.7%화18.8%.중위질병진전시간분별위5.9개월화3.9개월,중위총생존기분별위10.9개월화8.9개월.차이균유통계학의의(P<0.05).결론 여단순사용IFL방안상비.패벌단항연합IFL방안능진일보연장기왕접수과이초산박위주화료방안적전이성결직장암환자적생존시간,치료내수성량호.
Objective To evaluate the efficacy of bevacizumab in combination of irinoteean,fluomuracil and leucovorin for metastatic colorectal cancer treated by failed prior oxaliplatin -based regiment. Methods Sixty-two patients were randomly divided into two groups, group A of 30 patients received bevacizumab plus irinotecan, fluorouracil and leucovorin, group B of 32 patients received irinotecan, fluorouracil and leucovorin. The response rate,change of tumor markers,one year survival rate and safety were observed. Results Tumor response rate was 30% in group A, 21.8% in group B respectively. Disease control rate (CR+PR+SD) was 80% in group A, 50% in group B. The obvious change of concentration of tumor markers was observed between pre-treatment and post-treatment, which was significantly different in group A(P<0.05). One year survival rate, median of time to progression and median duration of survival between group A and group B were 26.7% vs 18.8%, 5.9 months vs 3.9 months, 10.9 months vs 8.9 months(P<0.05). The adverse effect in group A was the same as group B. Bevacizumab was associated with hypertension and bradycardia. Conclusions The chemotherapy of bevacizumab combined with irinotecan, fluorouracil and leucovorin results in better efficacy in patients with progressive metastatic colorectal cancer.